Methylphenidate HCl

Methylin

Strengths & Sizes

Methylphenidate HCl
Methylphenidate HCl

Note: product and packaging images are not actual size

  • NDC#31722-926-01
  • UPC Code331722926010
  • Imprint260/AT
Methylphenidate HCl
Methylphenidate HCl

Note: product and packaging images are not actual size

  • NDC#31722-927-01
  • UPC Code331722927017
  • Imprint261/AT
Methylphenidate HCl
Methylphenidate HCl

Note: product and packaging images are not actual size

  • NDC#31722-928-01
  • UPC Code331722928014
  • Imprint262/AT

Indications

Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride chewable tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.